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This issue of Translations
highlights a number of
individuals and teams
that represent the very
best Jefferson has to offer in terms of
research, clinical care, and education. The
new Advanced Heart Failure Center is 
thriving under the leadership of Dr. Paul
Mather, which makes the Jefferson Heart
Institute even more comprehensive. The
Center for Translational Medicine continues
its cutting-edge research with the expertise
of Dr. Andrea Eckhart, who runs the
Eugene Feiner Laboratory for Vascular
Biology and Thrombosis.
I am proud to showcase in this issue the
accomplishments of our faculty, many of
whom were recognized this year — some
by Dean Nasca for their efforts in education
and mentoring, and others by the National
Institutes of Health with new R01 grants.
This issue also profiles the contributions 
of the divisions of Gastroenterology and
Hepatology; Critical Care, Pulmonary,
Allergic, and Immunologic Diseases; and
Clinical Pharmacology.
Finally, I would like to express my gratitude
to the many individuals, foundations, and
organizations who have supported the
Department of Medicine during the past
fiscal year. Their contributions continue to
be critical as we strive to bring exceptional
research and clinical care to the
Philadelphia region.
Arthur M. Feldman, MD, PhD
Magee Professor of Medicine and
Chairman of the Department
From the
ChairmanJefferson’s Heart Failure Center, estab-
lished in 2003, came into existence at an
opportune time. Paul Mather, MD,
Director of the Advanced Heart Failure
and Cardiac Transplant Center and
Associate Professor of Medicine, notes
that “heart failure is the only disease
that is growing as the population ages.”
Eighty percent of people over 65 have
some form of heart failure, and there are
550,000 new cases a year in the U.S. As
many as 287,000 die from the disease
annually, and it
accounts for 7 
percent of all U.S.
healthcare costs.
In addition to saving
lives of patients who
have suffered heart
attacks, physicians
at the new Jefferson
center also seek to
reduce the injury
that creates or triggers the attacks in the
first place. “Heart failure treatment has
changed significantly over the past 20
years,” explains Dr. Mather, who joined
Jefferson from Temple University in early
2004. He notes that while the approach
formerly targeted patients’ symptoms, 
it now seeks to identify the underlying
causes. “We have shifted to a model
that is both hemodynamic (symptom-
based) and neurohormonal. We try to
fool the body’s compensatory mechanism
to retard the progress of the disease.”
While there are already four other heart
transplant centers in Philadelphia, Dr.
Mather emphasizes the need for another
program in the region, to respond to the
number of patients with heart failure,
which is growing exponentially. “At 
present, centers must routinely turn away
a majority of patients,” he says. “This
program fills a niche within the Jefferson
medical healthcare system to address
advanced heart failure, which provides a
comprehensive, cutting-edge approach
to the disease process.” 
Jefferson’s program is a “fresh, aggressive
new program built on a foundation of
extensive experience,” says Dr. Mather. 
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Jefferson’s Heart Failure Center faculty and
staff (front, left to right): Kim Phillips;
Patricia Gray; Sharon Rubin, MD; Lisa
Wus; Michelle Munday; Sharon
Millinghausen; Theresa Pondok, MD; and
Paul Mather, MD; (back) Jill Reynolds;
Kimberly Evans; Barbara Ebert, CRNP;
Heather Miller, RN, MSN; Natalie Pierson,
RN, BSN; Rebecca O’Shea; Anne Canny,
RN, MSN; and David Whellan, MD, MHS
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Andrea Eckhart, PhD, Associate Professor
of Medicine, was one of the original fac-
ulty members to join the department’s
progressive research initiative, the Center
for Translational Medicine, directed by
Walter Koch, PhD. She has always had
an interest in understanding the cause of
diseases — particularly hypertension and
atherosclerosis. A move to the U.S. from
her native Canada provided her with the
opportunity to explore these interests.
After completing




gy, she joined Dr.
Koch’s lab at Duke
University as a
postdoctoral fellow
in 1997. She was
subsequently hired
at Duke University
as a faculty mem-
ber in 2000.
Eckhart Contributes Cutting-Edge Research
2
Center for Translational Medicine
Andrea Eckhart, PhD, directs the
Eugene Feiner Laboratory for
Vascular Biology and Thrombosis
Medical Faculty Garners
New NIH Grants
During the first half of 2004, 12 Jefferson
Department of Medicine faculty members
were awarded grants from the National
Institutes of Health. Awards vary in length
from one to five years. 
In the division of Infectious Diseases 
and Environmental Medicine, Roger
Pomerantz, MD, Division Director,
received a new R01 for HIV/AIDS Intravirion
Reverse Transcription and Virucides. Also
within the division, Associate Professor 
Hui Zhang, PhD, received a new R01 for
Cytidine Deaminase and HIV-1 Replication;
Assistant Professor Phyllis Flomenberg,
MD, received a new R21 for Human T
Cell Responses to Vaccinia Vaccine; and
Professor Lance Simpson, PhD, received a
new-NIAID Contract for Pharmacokinetic
Studies on Botulinum Toxin.
In the Center for Translational Medicine,
Walter Koch, PhD, Director of the center,
was awarded an R01 competitive renewal
for Targeting betaARK1 in Heart Failure.
Andrea Eckhart, PhD, Associate
Professor, was awarded a new R01 for
Transgenic Targeting of Vascular G Protein
Signaling. (See the profile on Dr. Eckhart
above.)
In the division of Hematology, Barbara
Schick, PhD, Professor, received a new
R21 for Deletion of Serglycin Proteoglycan
Gene in Mice.
In Cardiology, Paul Mather, MD,
Associate Professor of Medicine, received
a subcontract for a new NIH-funded 
clinical trial in Genetic Modulation of Left
Faculty News
Ventricular Recovery. (See more about 
Dr. Mather’s work in the cover story.)
In the division of Endocrinology, Diabetes,
and Metabolic Diseases, Division Director
Barry Goldstein, MD, PhD, received a
new R01 for Adiponectin: Vascular
Responses and Signaling Mechanisms.
In Rheumatology, Division Director Sergio
Jimenez, MD, received a Competing
Renewal T32 for Training in Molecular
Rheumatology and Orthopedics.
Bruce Boman, MD, PhD, Director of the
division of Medical Genetics, received a
planning grant award for AP4 Center for
Studies on Hereditary Colorectal Cancer.
Also in Medical Genetics, Professor
Ronald Myers, PhD, received a new
R21 for Tailored Messaging in Colorectal
Cancer Screening.
One of the things that appealed to Dr.
Eckhart about the Center for Translational
Medicine is that it is very collaborative,
which she sees as unique to Jefferson.
“The center strives to expand research
efforts by taking advantage of the 
expertise available within the entire 
community,” she says. Dr. Eckhart also
notes that the center’s labs are not
islands that operate distinctly. “This is a
cooperative environment,” she explains.
“Our sharing encourages much more
efficient use of precious government
funding and donations.”
Dr. Eckhart explains that although the
center is still expanding, the labs, such as
the one she runs — the Eugene Feiner
Laboratory for Vascular Biology and
Thrombosis — are already doing research
funded by the NIH. Also in her lab are
three technicians, Charles Druckman,
Elizabeth Mandel, and Troy Wilkins, and
two post-docs, Drs. Rui-Hai Zhou, MD,
and David Harris, PhD. She consults 
regularly with Geno Merli, MD, in Internal
Medicine and Howard Weitz, MD, in
Cardiology to explore possible research
her lab could undertake that would directly
incorporate their clinical observations. 
Dr. Eckhart’s research interests are in the
area of hypertension. Her focus is on
understanding how receptors — the 
proteins that help to establish blood
pressure by binding hormones including
epinephrine — change their signaling in
vascular smooth muscle under disease
conditions. “Antihypertensive therapeu-
tic strategies are currently inadequate to
decrease high blood pressure in a 
significant proportion of patients suffering
from this disease,” she says. Dr. Eckhart’s
lab has already developed a method to
decrease blood pressure using a novel
inhibitor of certain receptor pathways
important in causing vasoconstriction. 
It is currently being studied in animal 
models of the disease, but it is hoped that
strategies like this will soon be assessed
in clinical trials. These trials will hopefully
lead to the development of new antihy-
pertensive drugs and methods of 
treatment for the disease.
“Here at the Center we are eager to
contribute to improved patient care
through the development of novel 
therapeutic strategies,” Eckhart says. Her
research, begun at the laboratory bench,
will eventually transition to the bedside,
providing enhanced and state-of-the-art
care for patients at Jefferson.
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3Heart Failure Center
Continued from page 1
The center stresses interpersonal patient
care and a multidisciplinary approach that
integrates science, health, psycho-social












The Advanced Heart Failure Center will
work closely with another innovative pro-
gram in the Department: The Center for
Translational Medicine, which seeks to
bring state-of-the-art research “from 
the bench to the bedside.” Dr. Mather
explains that, for cardiology research,
center director Walter Koch, PhD, and his
team “are the bench, and we are 
the bedside.”
Dr. Mather himself has been involved in
some 600 transplants over a decade. He
is joined by two new heart failure cardi-
ologists: Sharon Rubin, MD, who comes
from Temple University, has eight years’
experience, and has been involved in
some 300 transplants; and David
Whellan, MD, MHS, a former Duke 
faculty member. Heart Failure coordinators
Anne Canny, RN, MSN, and Natalie
Pierson, RN, BSN, joined the program in
April 2004, and transplant nurse Barbara
Ebert, CRNP, came on August 1 as 
coordinator for the Heart Failure program, 
to assist with dietary issues, social work
needs, and any related kidney and liver
problems. For heart transplants, the
Heart Failure Center teams with the 
surgical transplant team in the division 
of Cardiothoracic Surgery. 
The Cardiac Transplant Center received
government transplant approval on June
30, 2004. The first transplant patient
was listed in November 2004, and the
results of the first cardiac transplant at
Jefferson will be reported shortly. “I am
honored to play a role in Jefferson’s ever-
expanding commitment to the best in
cardiac care,” says Dr. Mather.
Jefferson’s Hepatology and Liver Transplant Program Achieves Success
Gastroenterology and Hepatology
The one-year survival rate for the 24 
primary patients who have had liver
transplants at Jefferson since June 4,
2003, has been 100 percent. This is up
from 92.5 percent for the 35 primary
patients in 2003 and 2004. The standard
across the country is currently 85 percent.
Victor Navarro, MD, is the Director of
Jefferson’s Hepatology and Liver
Transplant Program, which oversees the
clinical care of transplant patients. Dr.
Navarro, who joined the Jefferson faculty
in January of 2002, and Stephen Herrine,
MD, Associate Director, were joined this
July by medical hepatology fellow
Simona Rossi, MD, who will become part
of the full-time faculty in 2005. 
Dr. Navarro’s team of hepatologists 
is part of Jefferson’s division of
Gastroenterology and Hepatology, 
creating a multifaceted clinical and 
training program. His group oversees the
training of a clinical nurse practitioner,
fellows, and residents in liver disease. 
Since Dr. Navarro’s arrival, the liver
research program has expanded to
include a wide array of investigations, such
as clinical drug trials as well as studies in
transplantation, drug safety, sociological
and epidemiological hepatitis C research,
and new molecular approaches to the
diagnosis of liver cancer. His group’s
research has been presented at several
recent national meetings.
Drs. Navarro and Herrine see all referrals
of patients for liver transplantation, 
following a structured procedure that
evaluates the risks and needs for surgery,
as well as psychosocial and other patient
issues. Working with Karen Pine, RN, 
the pre-transplant coordinator — named
“Transplant Coordinator of the Year” 
by the Delaware Valley Chapter of the
American Liver Foundation — and 
transplant social worker Joan Tannebaum,
MSW, the medical staff works hand in
hand with surgeons Ignazio Marino, MD,
and Cataldo Doria, MD, who take a
greater role following the operation.
Natalie Fraser, RN, is the program’s 
post-transplant coordinator. The program
will soon expand from two to three
nurse coordinators.
The transplant program has grown 
to over 150 patients awaiting the 
procedure. Jefferson receives referrals
from throughout New Jersey, Delaware,
and Pennsylvania. “The hospital led the
way in expediting the process of patient
evaluation, which was reduced from
between six and nine months to as quick
as one month,” says Dr. Navarro. “While
the number of transplants has been 
consistent, the outcomes have improved 
significantly, thanks to our procedures and
Dr. Marino’s team of gifted surgeons.”
The program has also implemented 
innovative management protocols,
including treatment of hepatitis C both
before and after surgery as well as 
transplantation in HIV-positive individuals
with liver failure. It has also begun a multi-
disciplinary approach to liver tumors — 
a common complication in patients with
cirrhosis. Dr. Navarro is confident that
the commitment of his team will translate
into continued success for the program
and its patients.
Jefferson’s liver transplant team, from
left to right (front): Simona Rossi,
MD; Joan Tannebaum, MSW; and
Victor Navarro, MD; (back): Timothy
Weimer, RN; Karen Pine, RN; Natalie
Fraser, RN; Cataldo Doria, MD; and
Carlo Ramirez, MD
Paul Mather, MD, directs the
Jefferson Heart Failure Center
 Translations_Newsltr  1/21/05  4:03 PM  Page 5
3
et al.: Jefferson Translations, Vol. 2, No. 1, Fall/Winter 2004-2005
Published by Jefferson Digital Commons, 2009
Taking a Closer Look at Asthma
Critical Care, Pulmonary, Allergic, and Immunologic Diseases
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“Asthma is a disease affecting 15 million
Americans, it places a huge burden on
our health system, and we don’t know
what causes it,” says James Zangrilli,
MD, Assistant Professor of Medicine in
the division of Critical Care, Pulmonary,
Allergic, and Immunologic Diseases. He 
is also director of the Ambulatory Care
Clinic and the Pulmonary/Critical Care
Fellowship Training Program. Dr. Zangrilli’s
specialty is asthma and airways inflam-
mation, and he studies the cell biology
that is particular to these ailments.
Over the last two decades, research 
has focused on a specific kind of inflam-
mation, caused by certain cells: T helper
lymphocytes and eosinophils. While most
asthma research focuses on recruitment
and management of those cells, Dr.
Zangrilli focuses on the resolution of the
inflammation process — what physiologi-
cal mechanisms the body might use to
reduce the inflammation altogether. “The
theory of persistent asthma is that it is
caused by the failure of those mechanisms,”
he explains.
Research at Jefferson has established a
human model in which a tiny amount of
antigen (such as ragweed) is placed in a
small segment of the subject’s lung; this








attack. “The beauty of the model,” says
Dr. Zangrilli, “is that we can observe the
inflammation process over time; we can
harvest airway cells, tissues, and secretions
at baseline during periods of initiation,
maintenance, and resolution." This creates
a picture of asthma over a certain period —
whether it is 24 hours or 2 weeks.
Dr. Zangrilli's future research will seek to
characterize the cells and specific activities
involved in this process over time and will
include a murine model in collaboration
with Angela Haczku, MD, PhD, at the
University of Pennsylvania.
Another initiative of Dr. Zangrilli’s this
year is to establish a comprehensive 
outpatient asthma center at Jefferson. 
“We hope this will serve as an important
resource for the Jefferson community
and the Philadelphia area, and as a 
center for referrals and second opinions
as well as providing an anchor for clinical
research trials.”
Jefferson’s interventional endoscopy 
program has expanded with the addition
of David Loren, MD. Dr. Loren became
Assistant Professor of Medicine in the
division of Gastroenterology and
Hepatology (GI) after completing an
advanced endoscopy fellowship at
Jefferson in June 2003. As a fellow, 
Dr. Loren was mentored by Thomas
Kowalski, MD, Jefferson’s Medical Director
of Gastrointestinal Endoscopy, who is a
nationally recognized leader in advanced
endoscopy and pancreatic disease. 
As a unit, Jefferson’s is the busiest 
academic endoscopy program on the
East Coast, and one of the top five in
the country, performing more than
15,000 procedures annually. “This 
clinical volume allows for the opportunity
to train fellows in procedures that are 
complex and relatively uncommon,” 
Dr. Loren explains. During his fellowship
he gained experience in all aspects of
endoscopy, in literally hundreds of 
procedures. 
Dr. Loren joins the faculty as a member
of the pancreaticobiliary service and has
been named Director of Endoscopic
Research in the Digestive Disease Division
of Thomas Jefferson University Hospital.
His clinical and research interests focus on
endoscopic approaches to GI oncology,
endoscopic management of pancreatic
diseases, and endoscopic outcomes
research. His collaborations with Barry
Goldberg, MD, Professor of Radiology,
investigate novel applications of endoscopic
ultrasound in gastrointestinal cancers.
Dr. Loren is currently pursuing his 
master’s degree in Human Investigation
and Clinical Pharmacology through
Jefferson’s NIH K30 program (see the
article on p. 5). As a clinical investigator,
Dr. Loren has established a relationship
with Bruce Boman, MD, PhD, Director 
of the division of Medical Genetics, to
explore the management of patients who
are at increased risk for certain kinds of
hereditary cancer. Dr. Loren is also the
module leader for a section on hereditary
GI cancer at Jefferson Medical College. 
“The NIH has called for a nationwide
mandate to improve the quality of GI
endoscopic research, and endoscopic
outcomes and utilization in particular,”
says Dr. Loren, who notes that this effort
was led by Sidney Cohen, MD, Professor
of Medicine and Director of Research
Programs in GI at Jefferson. “I have been
reaching out to the many strengths at
Jefferson to help develop an endoscopic
program that will be a leader in research
and clinical care, both locally and nation-
ally,” he says. “I feel extremely fortunate
to be a member of such an experienced
team of distinguished colleagues.”
New Faculty Recruit in Endoscopic Research
Assistant Professor David Loren, MD,
joins the Jefferson endoscopy program
James Zangrilli, MD, does 
asthma research in the
Pulmonary Division
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Master’s Program Targets Human Investigation
Education/Clinical Pharmacology
In 1999 Jefferson created a training 
program offering a Master’s of Science 
in Pharmacology focusing on Human
Investigation, which capitalizes on
Jefferson’s extensive patient-oriented
research programs—more than 300 each
year. Scott Waldman, MD, PhD, FCP, the
Samuel M. V. Hamilton Professor and
Director of the division of Clinical
Pharmacology, directs the program.
The program seeks to train clinicians 
and doctoral-level candidates in how to
provide patient-based and patient-oriented
research. The two-year program trains 
no more than 10 individuals each year,
integrating coursework with practical,
mentored research experience. 
One of close to 50 or so programs in 
the United States at academic medical
centers, the program was created in part
due to an NIH response to the dwindling
numbers of clinicians who can engage in
translational and clinical research that
uses humans. These include dentists,
psychologists, and other healthcare
providers. 
“The paradigms that exist for research
are specialized for the examination of
molecules and cells,” says Dr. Waldman.
“With patients, there are a number of
ethical and privacy considerations, and
the technique required is much more
restricted than what is available to a 
laboratory researcher.”
Within a clinic, this can require adminis-
tering drugs, interacting with patients 
to obtain blood and/or tissue samples, 
or epidemiological research with a 
population of patients. Program trainees
learn how to work with patients and
how to ask answerable questions,
“which can avoid wasting resources,”
says Dr. Waldman.
The curriculum requires both 40 hours of
class time as well as participatory experi-
ences including conferences, seminars,
and rotations. Coursework explores topics
such as bioethics; federal policies and
regulations concerning human research;
scientific writing; management and 
organization; and information sciences.
Trainees do rotations at the Jefferson
Clinical Research Unit, where they learn
the nuts and bolts of how to conduct a
clinical trial, from conception through
the general protocol and IRB submission,
recruiting subjects, budgeting, collecting
data, and write-ups for publication or a
pharmaceutical company. 
Other rotations take place at the Cancer
Clinical Review Committee, which 
considers the scientific merit and human
protection issues, and at the Annals of
Internal Medicine, a premier journal
based nearby. Finally, the program requires
a research project that each student
undertakes with the help of a mentor.
The program is open not only to fellows
but to interns and residents as well as
faculty members. At present, one-third
of the people enrolled in the program
are Jefferson faculty. (Among them is 
Dr. David Loren, profiled on p. 4.) For
more information, visit www.tju.edu/
medicine/pharmacology/aca/
acapostdoctoral.cfm.
Clinical Pharmacology master’s 
program journal club in fall 2004,
from left to right: (seated) Walter
Kraft, MD; Mui Senh, BS; Roslyn
Varki, MD; Suzanne Leis, RN; Annette
Bell, MS, MT(ASCP)SH; and Howard
Greenberg, MD; (standing) Amit
Mittal, MD; Francisco Almeida, MD;
Theresa Pondok, MD; Scott Waldman,
MD, PhD, FCP; Terry Hyslop, PhD;
Stephanie Schulz, PhD; Li Gong,
PhD; and Constantine Daskalakis, ScD
Giving to Medicine
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William M. and Nadine Gibson Family 
Foundation
The Honickman Foundation
Mr. and Mrs. Donald F. Jones
The Robert J. Kahn Foundation
The Raymond Klein Charitable 
Foundation
Hyman Korman Family Foundation
The Bonnie Kroll Melanoma 
Memorial Fund
The Lisker Foundation
The G. Harold and Leila Y. Mathers 
Charitable Foundation 
The department gratefully acknowledges
the support of our donors.
Anonymous 
Jane Barsumian Trust/Mary Lyons Trust




Meyer and Stephanie Eglin Foundation
Estate of Allan J. Erslev 
Eugene Feiner 
Estate of Claire L. Formidoni
Mr. and Mrs. Stanford Frank
The Maxwell Strawbridge 
Charitable Trust
The John J. Murray Foundation, Inc.
Mr. and Mrs. Israel Roizman
Arline Schwarzman
Ervin Weiner
To learn more about giving opportunities
or to make a donation to the Department
of Medicine or one of our physicians,
please contact Susan Schiffrin at 215-955-
7556 or via e-mail at susan.schiffrin@
jefferson.edu. 
T
Gifts to the Department of Medicine, January 1, 2003–June 30, 2004
 Translations_Newsltr  1/21/05  4:00 PM  Page 1
5
et al.: Jefferson Translations, Vol. 2, No. 1, Fall/Winter 2004-2005
Published by Jefferson Digital Commons, 2009
Department of Medicine
1025 Walnut Street, Suite 822
Philadelphia, PA 19107-5083
Translations
Translations is published twice a year by the
Department of Medicine at Thomas Jefferson
University (www.tju.edu/medicine). For more
information call (215) 955-6946 or write to
the address below.
Arthur M. Feldman, MD, PhD, Magee Professor 
and Chairman of the Department of Medicine 
Edited by Alison Rooney   Design: JeffGraphics
Photography: Robert Neroni; Medical Media Services







“His vigorous mind and contagious
enthusiasm inspired colleagues and 
generations of medical students and
hematology fellows,” says Jaime Caro,
MD, of the Cardeza Foundation.
In 2004 Jefferson held the first Memorial
Lectureship in honor and remembrance
of Dr. Allan J. Erslev, the distinguished
Professor of Medicine, who died in
November of 2003. 
Copenhagen-born Dr. Erslev trained 
at Harvard and Yale before becoming
Director of the Cardeza Foundation in
1963. Ten years earlier, he had been the
first researcher to prove the existence of
the renal hormone erythropoietin, which
produces red blood cells. A genetically
engineered version of the hormone,
called EPO, was approved by the FDA in
1989 and benefits innumerable patients
with anemia, kidney dialysis, and renal
disease. 
Until 1985 Dr. Erslev was director of the
foundation, which benefited from his
work tremendously. Dr. Erslev was 
co-author of a standard textbook,
Hematology, as well as the paperback
Pathophysiology of Blood. He retired in
2002, after 43 years of teaching. 
In Memoriam: 
Dr. Allan J. Erslev
Dean Recognizes Faculty
with New Awards
Thomas J. Nasca, MD, Senior Vice
President and Dean, Jefferson Medical
College, has instituted two new awards
to recognize faculty for outstanding 
contributions to education and mentoring
at Jefferson. This year’s awardees were
honored at a May reception at the Union
League, hosted by Dr. Nasca.
Dean’s Citation for Significant
Contributions to the Advancement of
Education at Jefferson Medical College:
Salvatore Mangione, MD
John M. Spandorfer, MD
Serge A. Jabbour, MD
Gregory C. Kane, MD 
John W. Caruso, MD
Geno J. Merli, MD
Katherine Worzala, MD
Dale D. Berg, MD
Jay Herman, MD
Joseph A. DeSimone, Jr., MD
Matthew DeCaro, MD
Dean’s Citation for Faculty Mentoring: 
Scott A. Waldman, MD, PhD, FCP
Steven McKenzie, MD (left), Director
of the Cardeza Foundation and the
Division of Hematology, welcomed
2004 Erslev lecturer Joseph Prchal,
MD, PhD, of Baylor College of
Medicine, and several Erslev family
members, including (left to right)
granddaughter Maia Woodbury Erslev,
daughter Carole Erslev, her husband
Peter Woodbury, and daughter Wendy
Erslev. The portrait of Dr. Erslev now
hangs on the eighth floor of the
College Building at 1025 Walnut Street.
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